An Intervention to Reduce Inappropriate Medications in Long-term Care Residents With Severe Dementia

Dementia Clinical Trial

— OptimaMed  

Official title:

The OptimaMed Intervention to Reduce Inappropriate Medications in Long-term Care Residents With Severe Dementia: Results From a Quasi-experimental Intervention Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03539276
• Other study ID #: OptimaMed-1
• Status: Completed
• Phase: N/A
• Start date: March 2014
• Est. completion date: December 2015

Study information

• Verified date: May 2018
• Source: CHU de Quebec-Universite Laval
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An education intervention to promote medication reviews and interdisciplinary discussions within long-term care facilities with the aim of improving medication regimen among residents with severe dementia

Description:

A quasi-experimental study in three long-term care facilities. The intervention comprises an information leaflet for families of residents, a 90-minute knowledge exchange session for general practitioners, pharmacists and nurses and a list of "generally", "sometimes", and "exceptionally" appropriate medications for severe dementia residents

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: December 2015
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• diagnosis of dementia of any etiology

• severe dementia

Exclusion Criteria:

• admission less than 2 months before intervention

Related Conditions & MeSH terms

• Dementia
• Inappropriate Prescribing

Intervention

Behavioral:
• Knowledge exchange
OptimaMed

Locations

Country	Name	City	State
Canada	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale	Québec

Sponsors (5)

Lead Sponsor	Collaborator
CHU de Quebec-Universite Laval	Fonds de la Recherche en Santé du Québec, McGill University, Université de Montréal, Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Kröger E, Wilchesky M, Marcotte M, Voyer P, Morin M, Champoux N, Monette J, Aubin M, Durand PJ, Verreault R, Arcand M. Medication Use Among Nursing Home Residents With Severe Dementia: Identifying Categories of Appropriateness and Elements of a Successful Intervention. J Am Med Dir Assoc. 2015 Jul 1;16(7):629.e1-17. doi: 10.1016/j.jamda.2015.04.002. Epub 2015 May 13. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medication regimen	Active prescriptions	Four months post intervention
Secondary	Level of pain	Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC).; The French version of the PACSLAC tool is a validated observational scale in use in Quebec to assess discomfort / pain.; One point is added to the score for each PACSLAC item (n=60) observed over a 15-minute observation period; the sum of the four 15-minute observation periods gives the total score. The total score ranges from zero to sixty where zero represents no discomfort or pain and sixty a very high level of discomfort or pain.	Four months post intervention
Secondary	Level of agitation	Cohen-Mansfield Agitation Inventory () measures level of agitation. Sum of the number of times the Cohen-Mansfield Agitation Inventory items were observed during the four 15-minute observation periods.. The total score ranges from zero to one hundred where zero represents no agitation and one hundred a very high level of agitation.	Four months post intervention